http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ionis Pharmaceuticals (IONS) treatment for Alexander disease receives orphan drug designation from U.S. FDA
-
Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
-
Akcea Therapeutics (AKCA) Announces WAYLIVRA to Be Available on the NHS in England
-
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
-
Ionis to present at upcoming virtual investor conferences
-
Ionis Pharmaceuticals (IONS) announces NEJM publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
-
New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
-
Ionis Pharmaceuticals (IONS) to acquire remaining stake in Akcea Therapeutics (AKCA) for $18.15/sh
-
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
-
Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Highlight Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx))
-
Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Present Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx)
-
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
-
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
-
Ionis Pharmaceuticals to hold cardio-renal franchise webcast
-
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
-
Akcea Therapeutics (AKCA), Ionis (IONS) to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
-
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
-
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
-
Ionis reports second quarter 2020 financial results and recent business achievements
-
Akcea Reports Financial Results and Highlights for Second Quarter 2020
-
Akcea Therapeutics (AKCA) Announces Approval for Reimbursement of TEGSEDI in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
-
Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast
-
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
-
Biogen (BIIB) Begins Phase 4 Study Evaluating Benefit of SPINRAZA (nusinersen) in Patients Treated with Zolgensma (onasemnogene abeparvovec)
-
Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)
-
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
-
Akcea Appoints New Senior Vice President, Global Medical Affairs
-
Akcea Therapeutics (AKCA) Announces Appointment of New Chief Medical Officer
-
Akcea Announces Appointment of New Chief Medical Officer
-
Ionis Pharmaceuticals to hold neurology franchise webcast
-
Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
-
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
-
Biogen (BIIB) Announces New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA Continue to Demonstrate Sustained Benefit From Treatment
-
New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
-
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
-
Akcea (AKCA) announces approval for reimbursement of TEGSEDI in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
-
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
-
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
-
Akcea (AKCA) announces approval for reimbursement of TEGSEDI in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
-
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
-
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
-
Akcea (AKCA), Ionis (IONS) Announce Publication of L-T Clinical Data of TEGSEDI in Patients with Polyneuropathy Driven by hATTR Amyloidosis Demonstrating Sustained Improvements
-
Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Eve
-
Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Eve
-
Biogen (BIIB) Announces New SPINRAZA Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of SMA Patients
-
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
-
Akcea Therapeutics (AKCA) Announces Appointment of New CFO
-
Akcea Announces Appointment of New Chief Financial Officer
-
Akcea Therapeutics (AKCA) Announces Approval for Reimbursement of TEGSEDI in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
-
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
